National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 36807-36808 [2017-16522]
Download as PDF
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
mstockstill on DSK30JT082PROD with NOTICES
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review and
discussion of grant applications.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Name of Committee: National Advisory
Child Health and Human Development
Council.
Date: September 14, 2017.
Open: September 14, 2017.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: The agenda will include opening
remarks, administrative matters, Director’s
Report, Division of Extramural Research
Report and, other business of the Council.
Place: National Institutes of Health,
Building 31, C-Wing, Conference Room 6,
9000 Rockville Pike, Bethesda, MD 20892.
Closed: September 14, 2017.
Time: 1:00 p.m. to Adjournment.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, C-Wing, Conference Room 6,
9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Della Hann, Ph.D.,
Director, Division of Extramural Research,
Eunice Kenney Shriver, National Institute of
Child Health and Human Development, NIH,
6710 Rockledge Blvd., MSC 7002, Bethesda,
MD 20892, 301–496–8535.
Any interested person may file written
comments with the committee by forwarding
the statement to the contact person listed on
this notice. The statement should include the
name, address, telephone number, and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxis, hotel, and airport shuttles,
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
In order to facilitate public attendance at
the open session of Council in the main
meeting room, Conference Room 6, please
contact Ms. Lisa Kaeser, Program and Public
Liaison Office, NICHD, at 301–496–0536 to
make your reservation, additional seating
will be available in the meeting overflow
rooms, Conference Rooms 7 and 8.
Individuals will also be able to view the
meeting via NIH Videocast. Please go to the
following link for Videocast access
instructions at: https://www.nichd.nih.gov/
about/advisory/nachhd/Pages/virtualmeeting.aspx.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment program, National
Institutes of Health, HHS).
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
Dated: August 1, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–16520 Filed 8–4–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; JHU Translational
Immuno-Engineering BTRC (2018/01).
Date: September 26, 2017.
Time: 09:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Blvd., Suite 959, Democracy Two, Bethesda,
MD 20892, (301) 451–3398, hayesj@
mail.nih.gov.
Dated: August 1, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–16533 Filed 8–4–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
36807
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Pilot Clinical Trials
Targeting HIV–1 Reservoirs in Children
(U01).
Date: August 23, 2017.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: J. Bruce Sundstrom, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Rm. 3G11A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–669–5045,
sundstromj@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 1, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–16523 Filed 8–4–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\07AUN1.SGM
07AUN1
36808
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Asthma and Allergic
Diseases Cooperative Research Centers.
Date: September 7–14, 2017.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Paul A. Amstad, Ph.D.,
Scientific Review Officer, Scientific Review
Program, NIAID/NIH/DHHS, Division of
Extramural Activities, Room 3G41, 5601
Fishers Lane, Bethesda, MD 20892–7616,
240–669–5067, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 1, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–16522 Filed 8–4–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: The Development of a
Bispecific, Biparatopic Antibody-Drug
Conjugate to GPC3 for the Treatment
of Human Liver Cancers
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an Exclusive Patent License to Salubris
Biotherapeutics, Inc. (Salubris), located
in Gaithersburg, Maryland, to practice
the inventions embodied in the patent
applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before August 22,
2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: David A. Lambertson, Ph.D.,
Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:14 Aug 04, 2017
Jkt 241001
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702; Telephone: (240) 276–
6467; Email: david.lambertson@nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: (A) U.S.
Provisional Patent Application 61/
654,232 entitled ‘‘High-affinity
Monoclonal Antibodies To Glypican-3
And Use Thereof’’ [HHS Ref. E–136–
2012/0–US–01], PCT Patent Application
PCT/US2013/043633 entitled ‘‘Highaffinity Monoclonal Antibodies To
Glypican-3 And Use Thereof’’ [HHS Ref.
E–136–2012/0–PCT–02], Chinese Patent
Application 201380039993.7 entitled
‘‘High-affinity Monoclonal Antibodies
To Glypican-3 And Use Thereof’’ [HHS
Ref. E–136–2012/0–CN–03], Japanese
Patent Application 2015–515243
entitled ‘‘High-affinity Monoclonal
Antibodies To Glypican-3 And Use
Thereof’’ [HHS Ref. E–136–2012/0–JP–
04], South Korean Patent Application
10–2014–7037046 entitled ‘‘Highaffinity Monoclonal Antibodies To
Glypican-3 And Use Thereof’’ [HHS Ref.
E–136–2012/0–KR–05], Singapore
Patent Application 11201407972R
entitled ‘‘High-affinity Monoclonal
Antibodies To Glypican-3 And Use
Thereof’’ [HHS Ref. E–136–2012/0–SG–
06], and United States Patent 9,409,994
entitled ‘‘High-affinity Monoclonal
Antibodies To Glypican-3 And Use
Thereof’’ [HHS Ref. E–136–2012/0–US–
07], and all continuing U.S. and foreign
patents/patent applications for the
technology family; and (B) U.S.
Provisional Patent Application 61/
477,020 entitled ‘‘Human Monoclonal
Antibody Specific for Glypican-3 And
Use Thereof’’ [HHS Ref. E–130–2011/0–
US–01], PCT Patent Application PCT/
US2012/034186 entitled ‘‘Human
Monoclonal Antibodies Specific for
Glypican-3 And Use Thereof’’ [HHS Ref.
E–130–2011/0–PCT–02], Chinese Patent
201280029201.3 entitled ‘‘Human
Monoclonal Antibodies Specific for
Glypican-3 And Use Thereof’’ [HHS Ref.
E–130–2011/0–CN–03], European Patent
2699603 entitled ‘‘Human Monoclonal
Antibodies Specific for Glypican-3 And
Use Thereof’’ [HHS Ref. E–130–2011/0–
EP–04], and validated in France [HHS
Ref. E–130–2011/0–FR–09], Germany
[HHS Ref. E–130–2011/0–DE–08] and
the United Kingdom [HHS Ref. E–130–
2011/0–GB–10] and lodged in Hong
Kong [HHS Ref. E–130–2011/0–HK–11],
United States Patent 9,206,257 entitled
‘‘Human Monoclonal Antibodies
Specific for Glypican-3 And Use
Thereof’’ [HHS Ref. E–130–2011/0–US–
05], United States Patent 9,394,364,
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
entitled ‘‘Human Monoclonal
Antibodies Specific for Glypican-3 And
Use Thereof’’ [HHS Ref. E–130–2011/0–
US–06], European Patent Application
15188264.4 entitled ‘‘Human
Monoclonal Antibodies Specific for
Glypican-3 And Use Thereof’’ [HHS Ref.
E–130–2011/0–EP–07], United States
Patent Application 15/090,873 entitled
‘‘Human Monoclonal Antibodies
Specific for Glypican-3 And Use
Thereof’’ [HHS Ref. E–130–2011/0–US–
12], Chinese Patent Application
201610290837.3 entitled ‘‘Human
Monoclonal Antibodies Specific for
Glypican-3 And Use Thereof’’ [HHS Ref.
E–130–2011/0–CN–13], European Patent
Application 16166924.7 entitled
‘‘Human Monoclonal Antibodies
Specific for Glypican-3 And Use
Thereof’’ [HHS Ref. E–130–2011/0–EP–
14], and all continuing U.S. and foreign
patents/patent applications for the
technology family, to Salubris. The
patent rights in these inventions have
been assigned to and/or exclusively
licensed to the Government of the
United States of America.
With respect to persons who have an
obligation to assign their right, title and
interest to the Government of the United
States of America, the patent rights in
these inventions have been assigned to
the Government of the United States of
America.
The prospective Exclusive Patent
License territory may be worldwide for
the following field of use:
The development and commercialization
of a bispecific, biparatopic antibody-drug
conjugate (ADC) having:
(1) The CDR sequences of both the hYP7
and HN3 anti-GPC3 monoclonal antibodies;
and
(2) a microtubule inhibitor payload
including, but not limited to, auristatin and
mertansine;
for the treatment of human liver cancer. The
licensed field of use excludes any (a) nonspecified immunoconjugates, including, but
not limited to, chimeric antigen receptors
(CARs) and variants thereof, immunotoxins,
ADCs with payloads that are not microtubule
inhibitors, and monospecific versions of the
aforementioned immunoconjugates, and (b)
unconjugated antibodies.
The present inventions to be licensed
concern monoclonal antibodies that are
specific for the cell surface domain of
GPC3: HN3 and hYP7. These antibodies
can potentially be used for the treatment
of GPC3-expressing cancers such as
HCC. In the subject situation, the
antibodies can be used in conjunction to
target a toxic payload specifically to
GPC3-expressing cells, leading to the
selective destruction of the cancerous
cells.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
E:\FR\FM\07AUN1.SGM
07AUN1
Agencies
[Federal Register Volume 82, Number 150 (Monday, August 7, 2017)]
[Notices]
[Pages 36807-36808]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16522]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which
[[Page 36808]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Asthma and Allergic Diseases
Cooperative Research Centers.
Date: September 7-14, 2017.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The William F. Bolger Center, 9600 Newbridge Drive,
Potomac, MD 20854.
Contact Person: Paul A. Amstad, Ph.D., Scientific Review
Officer, Scientific Review Program, NIAID/NIH/DHHS, Division of
Extramural Activities, Room 3G41, 5601 Fishers Lane, Bethesda, MD
20892-7616, 240-669-5067, pamstad@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: August 1, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-16522 Filed 8-4-17; 8:45 am]
BILLING CODE 4140-01-P